Clinical trialNCT02935478SuspendedInterventional

Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation

SponsorSt. Louis UniversityEnrollment8Body WeightCirrhosisHCCHepatitis CHepatocellular CarcinomaObesity+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and has a grave prognosis. Obesity is an epidemic in the US.Patients with HCC and obesity are not candidates for liver transplantation, depriving them of the best option for cure from HCC. Recent studies have shown that blocking blood vessels to a particular portion of the stomach (bariatric or left gastric artery embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and result in weight loss.The purpose of this study is to determine if Left gastric artery embolization (LGAE) in patients with cirrhosis and HCC who are not transplant candidates due to morbid obesity, leads to clinically significant weight loss with eligibility for liver transplantation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Alex Befeler, MD
Professor of internal medicine- Gastreoenterology
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Keith Pereira, MD
Assistant professor of radiology-Interventional radiology
Principal Investigator
clinicaltrials.gov ↗
Kirubahara Vaheesan, MD
Associate professor of radiology-Interventional radiology
Principal Investigator
clinicaltrials.gov ↗
Mustafa Nazzal, MD
Assistant Professor of Surgery- abdominal transplant
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Saint Louis University
St Louis, Missouri, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Oct 2017
Primary completion: 31 Dec 2026
Completion: 31 Dec 2027
Last update posted: 6 Feb 2025
Registered enrollment: 8
Registry id: NCT02935478

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.